This information is for health professionals.
On this page: Flu vaccine claims (2023-2024) | COVID-19 vaccine | Publicly funded vaccine PINs
PharmaCare pays a fee when an authorized pharmacist, and in some cases non-pharmacist, administers a publicly funded vaccine to eligible B.C. residents. The fee for most publicly funded vaccines is $12.10. The fee for the COVID-19 vaccine is $18.00.
Key details:
Refer to the BCCDC’s B.C. Immunization Manual for criteria, immunization schedule and other important information.
PharmaCare allows pharmacies to claim the administration fee if a contracted nurse administers an influenza or COVID-19 vaccine.
Any nurse administering an influenza or COVID-19 vaccine in a B.C. pharmacy must be:
Flu vaccines can be administered by a pharmacy technician or pharmacy student, as authorized under the November 4, 2022, PHO, but must be supervised by a college registrant authorized under a health profession regulation.
Refer to COVID-19 claims and flu vaccine claims for procedures for those vaccines.
If administered to eligible patients for publicly funded vaccines:
Patients who are not eligible:
Once the annual campaign has officially begun (Sep 1 - June 1), pharmacies may submit claims for flu vaccinations.
The publicly funded flu vaccines for the 2023 – 2024 season are:
Private supply vaccinations are eligible for PharmaCare’s drug administration fee of $11.41.
Three publicly funded flu vaccines are also available for private supply.
Enter COVID-19 vaccinations in ImmsBC only. Records will be shared with PharmaNet, allowing PharmaCare to process the claim.
Vaccine product group | Brand | Vaccine product | PIN |
---|---|---|---|
COVID-19 | Vaxzevria Manufacturer: AstraZeneca |
COVID-19 vaccine (ChAdOx1-S [recombinant]) | 66127320 Applies to both 8-dose and 10-dose vials |
COVID-19 | Comirnaty® Manufacturer: Pfizer-BioNTech |
COVID-19 vaccine (tozinameran) | 66127303 Applies to both 6-dose and 10-dose vials |
COVID-19 | SPIKEVAX® Manufacturer: Moderna |
COVID-19 vaccine (elasomeran) | 66127304 |
Vaccine product group | Vaccine product | PIN |
---|---|---|
Haemophilus b conjugate | Act-HIB® | 66128205 |
Haemophilus influenzae type b conjugate | Hiberix® | 66128170 |
Hepatitis A | Avaxim™ | 66124760 |
Avaxim™ Pediatric | 66124831 | |
Havrix® 1440 | 66124768 | |
Havrix® Junior 720 | 66124769 | |
Vaqta® Adult | 66124794 | |
Vaqta® Pediatric | 66124795 | |
Hepatitis B | Engerix® B | 66124764 |
Engerix® B Pediatric | 66128130 | |
Recombivax HB® | 66124789 | |
Recombivax HB® Adult Dialysis | 66124790 | |
Recombivax HB® Pediatric | 66124791 | |
Human papillomavirus (2 strains) | Cervarix™ | 66127902 |
Human papillomavirus (9 strains) | Gardasil® 9 | 66128117 |
Measles, mumps, rubella | MMR-II™ | 66124781 |
Priorix™ | 66124834 | |
Measles, mumps, rubella, and varicella virus | Proquad® | 66128068 |
Priorix-Tetra | 66128069 | |
Meningococcal group B | Bexsero | 66128075 |
Meningococcal C conjugate | Meningitec™ | 66124832 |
Menjugate® | 66128114 | |
Neis Vac-C® | 66124782 | |
Pneumococcal conjugate 13-valent | Prevnar 13 | 66128070 |
Pneumococcal 23-valent | Pneumovax® 23 | 66124785 |
IPV (polio for travel indications) | Imovax® Polio | 66124773 |
Quadrivalent meningococcal conjugate | Menveo | 66128071 |
Menactra | 66128072 | |
Nimenrix® | 66128152 | |
Rabies | RabAvert® | 66124788 |
Smallpox and Monkeypox | Imvamune® | 66128369 |
Tetanus, diphtheria | Td Adsorbed | 66124793 |
Tetanus, diphtheria, acellular pertussis | Adacel® | 66124758 |
Boostrix® | 66127901 | |
Tetanus, diphtheria, acellular pertussis, polio adsorbed | Quadracel® | 66124787 |
Adacel® Polio | 66128131 | |
Boostrix®-Polio | 66128094 | |
Tetanus, diphtheria, acellular pertussis, polio, hepatitis B, haemophilus influenzae type b adsorbed | Infanrix hexa® | 66124776 |
Tetanus, diphtheria, IPV (polio for travel indications) | Td Polio Adsorbed | 66124792 |
Varicella | Varilrix® | 66124796 |
Varivax® III | 66124797 |
Section 8.10 – Pharmacist administration of drugs and vaccines